{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(9)"],"submitter":["Jin W"],"pubmed_abstract":["<b>Rationale:</b> Synergic reprogramming of metabolic dominates neuroblastoma (NB) progression. It is of great clinical implications to develop an individualized risk prognostication approach with stratification-guided therapeutic options for NB based on elucidating molecular mechanisms of metabolic reprogramming. <b>Methods:</b> With a machine learning-based multi-step program, the synergic mechanisms of metabolic reprogramming-driven malignant progression of NB were elucidated at single-cell and metabolite flux dimensions. Subsequently, a promising metabolic reprogramming-associated prognostic signature (MPS) and individualized therapeutic approaches based on MPS-stratification were developed and further validated independently using pre-clinical models. <b>Results:</b> MPS-identified MP"],"journal":["Theranostics"],"pagination":["3439-3469"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11209723"],"repository":["biostudies-literature"],"pubmed_title":["Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression."],"pmcid":["PMC11209723"],"pubmed_authors":["Jin W","Gao M","Zhang Y","Zhao Z"],"additional_accession":[]},"is_claimable":false,"name":"Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression.","description":"<b>Rationale:</b> Synergic reprogramming of metabolic dominates neuroblastoma (NB) progression. It is of great clinical implications to develop an individualized risk prognostication approach with stratification-guided therapeutic options for NB based on elucidating molecular mechanisms of metabolic reprogramming. <b>Methods:</b> With a machine learning-based multi-step program, the synergic mechanisms of metabolic reprogramming-driven malignant progression of NB were elucidated at single-cell and metabolite flux dimensions. Subsequently, a promising metabolic reprogramming-associated prognostic signature (MPS) and individualized therapeutic approaches based on MPS-stratification were developed and further validated independently using pre-clinical models. <b>Results:</b> MPS-identified MP","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-03-13T10:33:14.06Z","creation":"2025-08-12T03:04:54.478Z"},"accession":"S-EPMC11209723","cross_references":{"pubmed":["38948053"],"doi":["10.7150/thno.93962"]}}